Amino Acid Metabolism in Lupus

Michihito Kono1†, Nobuya Yoshida2*† and George C. Tsokos2*

1 Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Japan,
2 Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States

T cell metabolism is central to cell proliferation, survival, differentiation, and aberrations have been linked to the pathophysiology of systemic autoimmune diseases. Besides glycolysis and fatty acid oxidation/synthesis, amino acid metabolism is also crucial in T cell metabolism. It appears that each T cell subset favors a unique metabolic process and that metabolic reprogramming changes cell fate. Here, we review the mechanisms whereby amino acid transport and metabolism affects T cell activation, differentiation and function in T cells in the prototype systemic autoimmune disease systemic lupus erythematosus. New insights in amino acid handling by T cells should guide approaches to correct T cell abnormalities and disease pathology.

Keywords: cell metabolism, amino acid, T cell, systemic lupus erythematosus, amino acid transporters

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibody production, immune complex deposition, tissue inflammation and damage of multiple organs (1). SLE can affect practically all organs, including skin, kidney, and central nerve system (2–4). The etiology of SLE is multifactorial and includes contributions from genetic, environmental, hormonal and epigenetic factors (2). These factors, acting serially or simultaneously, lead to generalized breakdown of tolerance to self-antigens, which results in autoantibody production and tissue inflammation (5). T cells have a vital role in the pathogenesis of SLE. Many subsets of T cells, especially Th1, Th17, regulatory T (Treg) cells, and double-negative (CD4 CD8) T cells, are involved through distinct mechanisms in the development of organ inflammation in SLE (6). Since helper T cells can activate B cells to secrete antibodies, which are also involved in the lupus pathogenesis, T cells have earned claim as main therapeutic targets in patients with SLE (7).

Recent studies have shown that the differentiation and function of each T cell subset is controlled by intracellular metabolic processes (8–10). Cell metabolism operates mainly through glycolysis, fatty acid oxidation and amino acid metabolism including glutaminolysis (8–11). Amino acids are classified as essential (leucine, isoleucine, lysine, histidine, valine, threonine, phenylalanine, tryptophan, and methionine), conditionally essential (glutamine, arginine, cysteine, glycine, proline, and tyrosine), or non-essential (alanine, glutamate, serine, asparagine, and aspartate) (12). Essential amino acids cannot be synthesized within the body and must be supplied through dietary intake. Amino acid metabolism is used in many processes that are involved in cell proliferation, growth and cell function. Furthermore, amino acids are also critical for the biosynthesis of nucleotides (13). It has been documented that some amino acids such as leucine, methionine, glutamine, arginine, and alanine, are more essential than other amino acids during T cell activation and expansion or in determining distinct T cell fates (14, 15). The importance of glycolysis, and fatty acid oxidation/synthesis in lupus T cells has been extensively reviewed
elsewhere (8–10, 16–18). Here we summarize amino acid metabolism in mice and people with SLE with a focus on T cells.

**AMINO ACID TRANSPORTERS**

Amino acid transporters are important in transporting amino acids from the environment into the cell (19). T-cell receptor (TCR) stimulation triggers dramatic metabolic changes including increased glycolysis, pentose phosphate pathway activity, and glutaminolysis (19, 20). SLC7A5, known as large neutral amino acid transporter 1 (LAT-1), is a transporter dedicated to the transport of essential amino acids (21). SLC3A2, also known as CD98, is a transmembrane protein, which chaperones amino-acid transporters, including SLC7A5 SLC7A6, SLC7A7, SLC7A8, SLC7A10, and SLC7A11 (12), and enables them to execute their function. The LAT-1/CD98 heterodimer transports large hydrophobic amino acids, including the seven essential amino acids leucine, isoleucine, histidine, valine, phenylalanine, tryptophan, and methionine. Notably, the expression of LAT-1 and CD98 in T cells is induced after activation (19). Slc7a5−/− CD4+ T cells cannot respond to antigen, undergo clonal expansion or effector cell differentiation. Although Slc7a5−/− CD4+ T cells do not differentiate into Th1 and Th17 cells, differentiation into iTreg is not affected (22). LAT-1 deletion or inhibition blocks the expansion of IL-17 secreting γδ and CD4+ T cells in both human cells and imiquimod (a TLR7 agonist)-induced lupus and psoriasis-like animal models (Figure 1). The heterodimer comprising CD98 and SLC7A7 transports among other amino acids lysine, arginine, methionine, leucine, alanine, and cysteine (12). Interestingly, whole-exome sequencing in patients with childhood-onset SLE identified a SLC7A7 mutation to be linked to disease expression (23).

Alanine is also important in T cell activation. It is transported through SLC38A1 in CD4+ T cells and TCR stimulation induces its expression (12). Alanine deprivation impairs naïve and memory T cell activations, but it does not affect T cell effector functions (24). Although alanine can be made from pyruvate by a single transamination, extracellular alanine is used mainly for protein synthesis (12, 24).

Glutamine is the most abundant amino acid in the serum (25, 26). T cell stimulation promotes a rapid increase of glutamine uptake and activated T cells need more glutamine than naïve T cells (27). SLC1A5, known as alanine-serine-cysteine transporter 2 (ASCT2), is a transporter of neutral amino acids including glutamine (28). Although Slc1a5−/− CD4+ T cells do not affect

![Amino acid transporters and metabolism in lupus T cells.](image-url)

**FIGURE 1** | Amino acid transporters and metabolism in lupus T cells. Amino acid acquisition is crucial for cell function. Amino acid transporters play central roles in acquiring amino acids from the external environment. Some amino acids (e.g., leucine, methionine, glutamine, arginine, and alanine) are more essential than other amino acids in during T cell activation and expansion, or in determining different T cell fates in autoimmune diseases. Red arrows or letters indicate “enhance or active”, whereas blue arrows indicate “inhibit or inactivate”. ASCT2, alanine-serine-cysteine transporter 2; CaMK4, calcium/calmodulin–dependent protein kinase IV; CAT, cationic amino acid transporters; CREM, cAMP response element modulator; EAE, experimental autoimmune encephalomyelitis; ETC, electron transport chain; ICER, inducible cAMP early repressor; LAT-1, large neutral amino acid transporter 1; mTORC, mammalian target of rapamycin complex; OXPHOS, oxidative phosphorylation; PKM2, pyruvate kinase muscle isozyme 2; ROS, reactive oxygen species; SLE, systemic lupus erythematosus; TCA cycle, tricarboxylic acid cycle.
TCR-mediated activation, deletion of Scl1a5 impaired Th1 and Th17 cell differentiation (Figure 1) (27).

Arginine is transported through cationic amino acid transporters (CAT) (29), which are shared by lysine and ornithine. Elevation of arginine levels induces metabolic changes including a shift from glycolysis to oxidative phosphorylation in activated T cells and promotes the generation of central memory-like cells (30). Arginine and the transporter CAT-1 (SLC7A1) are also requisite for human T cell survival (31).

These findings demonstrate distinct roles for amino acid transporters in TCR/CD3-mediated T cell stimulation, differentiation, and function and indicate that manipulation of these transporters could serve therapeutic approaches for autoimmune diseases including SLE (Figure 1). Because several other amino acid transporters have not been studied carefully in T cells, further research is needed.

**AMINO ACID SENSORS**

Although multiple mechanisms are involved in sensing amino acids within the intracellular space, it has been well established that the presence or absence of amino acids is sensed by distinct signaling pathways which involve the mechanistic target of rapamycin (mTOR) or the general control nonderepressible 2 (GCN2) (32, 33).

mTOR activity is regulated by amino acid availability, energy levels, and growth factors (34). In mammalian cells mTOR forms two distinct complexes: the mTORC complex 1 (mTORC1) and mTORC2. In fact, mTORC1 senses various stress signals, including the accumulation of amino acids such as leucine, isoleucine, kynurenine, and glutamine (35, 36). Glutamine activates mTORC1 via its metabolic product α-ketoglutarate which is generated during glutaminolysis (37). Inhibition of the first enzyme of glutaminolysis, glutaminase 1, reduces the activity of mTORC1 under Th17-polarized conditions (38). mTORC activity is enhanced in Th17 cells and IL-4-producing double negative T cells resulting in the proinflammatory profile recorded in patients with SLE (39). During Th17 cell differentiation, mTOR is required for the induction of hypoxia-inducible factor 1α (HIF1α) which enhances glycolysis (40). In Th1 and Th17 cells, mTORC1 activity, and glycolysis are increased compared with Tregs and Tfh cells (40, 41). Sirolimus, a mTOR inhibitor, was reported to improve disease activity in patients with refractory SLE in a single-arm, open-label, phase I/II trial (42), and other non- randomized controlled studies have reported that sirolimus is efficacious in patients with SLE (Table 1) (43). Sirolimus normalized Th17/Treg balance and TCR-induced Ca2+ fluxing in patients with SLE (44, 45). Besides the effect on T cells, inhibition of mTOR in plasmacytoid dendritic cells reduced the production of type I interferons (58) and B cell stimulating factor BAFF-mediated B cell activation (59, 60). These results indicate that sirolimus can modify T, B, and plasmacytoid dendritic cell function (46). Further randomized controlled trials are needed to prove the efficacy and record the side effects of sirolimus in patients with SLE (47).

GCN2, a serine/threonine-protein kinase, also senses amino acid starvation by detecting uncharged transfer RNA (33, 61). It plays a vital role in the control of amino acid metabolism as a response to nutrient deprivation. Gcn2 deficiency significantly inhibits in vitro differentiation of Th9 cells but not Th1, Th2, and Treg cells in mouse model, and it ameliorated allergic airway inflammation in mice (62). On the other hand, myeloid cell deletion of Gcn2 in lupus-prone mice resulted in increased immune cell activation, humoral autoimmunity, renal pathology, and mortality (63). These results suggest that therapeutic inhibition of GCN2 should not be considered to treat SLE.

**GLUTAMINE METABOLISM**

Glutaminolysis has a vital role in energy production in proliferating cells including T cells. Because of the indispensable roles of glutaminolysis in the generation of pro-inflammatory effector T cells Th1 and Th17 cells, enzymes involved in glutaminolysis have been studied extensively.

Glutaminase, in charge of converting glutamine to glutamate, promotes Th17 cells through distinct mechanisms (38, 49). Glutaminase expression is controlled by the transcription factor inducible cAMP early repressor (ICER)/cAMP response element modulator (CREM) (38), which is known to be overexpressed in T cells both from patients with SLE or MRL/lpr lupus-prone mice (64, 65). The glutaminase 1 inhibitor Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) reduces Th17 cell differentiation and disease activity in animals subjected to experimental autoimmune encephalomyelitis (EAE) (38). BPTES also ameliorates disease activity in MRL/lpr mice (50). Glutamate oxaloacetate transaminase 1 (GOT1), which converts glutamate to α-ketoglutarate, an intermediate of the TCA cycle, also contributes to enhance Th17 cell differentiation through epigenetic processes (51). Selective inhibition of GOT1 with aminooxy acetic acid (AOA) treatment or short hairpin RNA (shRNA) silencing markedly decreased Th17 differentiation of murine T cells (51). Systemic AOA treatment or adoptive transfer of Got1 knockout Th17-polarized T cells ameliorated EAE (51). Furthermore, inhibition of glutaminolysis with the glutamine analog 6-Diazo-5-oxo-L-norleucine (DON) reduces the frequency of Tfh cells, exogenous antigen-specific germinal center responses, and the production of dsDNA antibody in lupus-prone B6.Sle1.Sle2.Sle3 mice after T cell-dependent immunization (52).

**BRANCHED-CHAIN AMINO ACID METABOLISM**

The branched-chain amino acids (BCAAs) include leucine, isoleucine, and valine. As the most abundant of essential amino acids, BCAAs are not only the substrates for synthesis of nitrogenous compounds, but they also serve as signaling molecules regulating the metabolism of glucose, lipid, and
protein synthesis, intestinal health, and immunity through special signaling networks, especially the phosphoinositide 3-kinase/protein kinase B/mTOR (PI3K/AKT/mTOR) signaling pathways, which are involved in the regulation of cell growth, metabolism, and survival. The leucine antagonist promotes mTORC1 activity and T cell function, impairs IL-2 and IFN-γ production in in vitro Th1 polarized murine T cells (66). Leucine is also essential for T cell function. Leucine promotes mTORC1 activity in Treg cells via the small G proteins RagA/B and Rheb1/2 to drive their suppressive activity by inducing the expression of inducible T cell costimulator (ICOS) and CTLA4. Mice bearing RagA-RagB- or Rheb1-Rheb2-deficient Treg cells developed a Scurfy-like autoimmune disease and have reduced effector Treg cell accumulation and function (48).

Unlike most other essential amino acids, BCAAs catabolism is initially catalyzed by transamination or decarboxylation by branched-chain amino acid aminotransferases (BCAT) or decarboxylation by branched-chain α-keto acid dehydrogenase enzyme complex (BCKDC). After these reactions BCAA metabolites are further converted to acetyl-CoA and succinyl-CoA and participate in the TCA cycle (67). In CD4+ T cells, BCAT negatively regulates mTOR and glycolysis. Activated T cells from cytosolic branched chain aminotransferase (BCATc)-deficient mice show increased mTORC1 activation compared to T cells from control mice. Furthermore, T cells from Bcatc−/− mice display higher rates of glycolysis (68). In another study, the oral administration of a leucine analogue, ERG240, selectively inhibited the activity of BCAT1, reduced the severity of collagen-induced arthritis in mice, and decreased glomerulonephritis in rats (69).

### SERINE METABOLISM

Serine is used in proliferating cells for protein synthesis as well as the synthesis of other amino acids, such as glycine and cysteine (70). Serine-derived glycine is used in nucleotide synthesis. Moreover, serine is also a precursor for the synthesis of lipids, such as phosphatidylserine and sphingolipids, which have central roles in apoptotic cell clearance and immune cell activation, respectively (71, 72). A key molecule which is associated with serine is the M2 isoform of pyruvate kinase (PKM2) because it ligates and allosterically activates its activity (73). Even in the absence of exogenous serine, PKM2 expression contributes to endogenous serine synthesis and to the maintenance of mTORC1 activity (74).

Upon T cell activation, upregulated enzymes of the serine, glycine, one-carbon (SGOC) metabolic network, increase processing of serine into one-carbon metabolism. Extracellular serine is required for optimal T cell proliferation both in vitro and in vivo. Shortage of dietary serine impairs pathogen-driven expansion of T cells in vivo. Serine supplies glycine and one-carbon units for de novo nucleotide biosynthesis in proliferating T cells, and one-carbon units from formate can rescue T cells from serine deprivation (75).

We previously reported that calcium/calmodulin–dependent protein kinase IV (CaMK4) binds to PKM2 and promotes pyruvate kinase activity. Activated PKM2 is requisite for the Th1 and Th17 differentiation (76). Because inhibition of CaMK4 ameliorates pathogenesis of SLE though a Th17 cell manner (77,
78), the serine/PKM2 metabolism axis represents a hub of abnormal T cells in autoimmunity and needs further attention.

Serine also supports mitochondrial metabolism. In Jurkat cells, the catabolic enzyme serine hydroxymethyltransferase (SHMT2) is required for mitochondrial and respiratory activity (79). It has been also shown that SHMT2 promotes inflammatory cytokine signaling, including that of type I interferons, by interacting with the deubiquitylating BRCC36 isopeptidase complex (BRISC) (80). Since it has been recently shown that an inactive form of SHMT2 dimer has the capacity to bind and inhibit BRISC (80), control of the SHMT2-BRISC interaction may represent a new target to control autoimmune diseases.

GLUTATHIONE/CYSTEINE METABOLISM

Glutathione is made from three amino acids: cysteine, glutamate, and glycine. Glutathione is important in the antioxidant defense, nutrient metabolism, and regulation of cellular events including gene expression, DNA and protein synthesis, cell proliferation and apoptosis, signal transduction, cytokine production and protein glutathionylation (81). Glutathione reduces intracellular reactive oxygen species (ROS) levels and inhibits Th17 cell differentiation (49, 82). Glutathione is reported to be decreased in the peripheral blood of patients with SLE (83). Glutathione regulates the elevating of mitochondrial transmembrane potential, which in turn activates mTOR in T cells from patients with SLE (53, 84). To date, N-acetylcysteine (NAC) has been used to correct glutathione levels because NAC is the cell-permeable precursor of cysteine which is the rate-limiting constituent of de novo reduced glutathione (53–55). Administration of NAC improves lupus disease activity and ameliorates organ damage mainly by blocking the mTOR pathway in T cells in humans and mice with SLE (56, 57).

Because cysteine contains sulfur, cysteine supports sulfur-dependent metabolism. As discussed above, cysteine is a key amino acid for glutathione function, as it supplies the sulfur necessary for the formation of the disulfide bridge in the glutathione disulfide (13), but its roles extend beyond glutathione synthesis. In humans, naïve T cells express none or very low levels of cysteine and cysteine transporters. Thus, early T cells activation does not require cysteine and cysteine transporters. However, upon activation, T cells rapidly upregulate the expression of cystine and cysteine transporters and display dependency on exogenous supply of cystine/cysteine for their proliferation (85).

CONCLUSIONS

During the last decade great progress has been achieved in the field of immunometabolism. It has now been established that T cell metabolism controls the fate and function of T cells. Amino acids are also crucial in T cell survival, function and differentiation. Besides glycolysis, amino acid metabolism is also involved in the pathogenesis in SLE and by inference to other autoimmune diseases. Although 2-deoxy-d-glucose monotherapy has partial efficacy in improving disease in lupus-prone mice, when combined with metformin, a mitochondrial electron transport chain complex I inhibitor, it leads to normalization of T cell metabolism and reversal of disease activity (94). These results revealed that monotherapy targeting only glycolysis is not sufficient to treat lupus-prone mice. Thus, the focus of research on T cell metabolism in lupus is expanding our understanding of amino acid metabolism.

Although many reports have shown that some metabolic pathways involving amino acids including glutamine, tryptophan, and cysteine can serve as therapeutic targets in lupus-prone mice, the tentative therapeutic targeting of metabolic pathways of other amino acids remains unclear. Sirolimus and NAC are undergoing rigorous clinical trials in patients with SLE (42, 43, 80) and they may end up serving as significant entries in the list of available therapeutic tools for these patients. There are though several challenges to overcome in order to exploit additional amino acid-related treatment targets. Although many studies using mouse models have revealed potential therapeutic targets in amino acid metabolism, further insights are needed from the ex vivo study of immune cells from patients with SLE. Such studies should be followed by properly designed clinical trials in patients with SLE and probably other autoimmune diseases. As all drugs display invariably side effects, cell/tissue targeted delivery should be considered (73, 95, 96).

In this brief review we presented evidence that amino acids are important in T cell function and aberrant metabolism may be linked to autoimmunity and related pathology. It appears that their central role in the control of the immune response is underwritten by being
indefensible for the generation of building blocks needed for cell proliferation, the generation of energy by controlling metabolic pathways, the control of epigenetic pathways, the production of phospholipids and the control of oxidative stress.

Amino acids and products of metabolic processes dictate the effector function of T cells and determine whether they will serve as regulators, instigators of inflammation or effectors of cytotoxicity. Alterations of the levels of metabolites within immune cells can be achieved by simply changing their levels in the environment or modulating the activity of transporters and intracellular metabolic enzymes. Drugs altering metabolism or supplementation of amino acids or metabolites or their precursors may prove of great value as modulators of T cell functions in the treatment and well-being of patients with autoimmune disease.

REFERENCES

1. Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol (2016) 12:716–30. doi: 10.1038/nrrheum.2016.186
2. Tsokos GC. Systemic lupus erythematosus. N Engl J Med (2011) 365:2110–21. doi: 10.1056/NEJMra1100359
3. Kono M, Yasuda S, Kato M, Kanetsuka Y, Kurita T, Fujieda Y, et al. Long-term outcome in Japanese patients with lupus nephritis. Lupus (2014) 23:1124–32. doi: 10.1177/0961203314536246
4. Aso K, Kono M, Kono M, Watanabe T, Shimizu Y, Ogata Y, et al. Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus. Lupus (2020) 29:1238–47. doi: 10.1177/0961203320938453
5. Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends Mol Med (2017) 23:615–35. doi: 10.1016/j.molmed.2017.05.006
6. Katsuyama T, Tsokos GC, Moulton VR. Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. Front Immunol (2018) 9:1088. doi: 10.3389/fimmu.2018.01088
7. Moulton VR, Tsokos GC. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest (2015) 125:2220–7. doi: 10.1172/JC78087
8. Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol (2020) 16:100–12. doi: 10.1038/s41584-019-0335-x
9. Kono M, Yoshida N, Tsokos GC. Metabolic control of T cells in autoimmunity. Curr Opin Rheumatol (2020) 32:192–9. doi: 10.1097/BOR.0000000000001685
10. Vukelic M, Kono M, Tsokos GC. T cell Metabolism in Lupus. Immunometabolism (2020) 2:e200009. doi: 10.20900/immunometab20200009
11. Kono M, Yoshih N, Maeda K, Skinner NE, Pan W, Kytariss VC, et al. Pyruvate dehydrogenase phosphatase catalytic subunit 2 limits Th17 differentiation. Proc Natl Acad Sci U S A (2018) 115:9288–93. doi: 10.1073/pnas.1805717115
12. Wang W, Zou W. Amino Acids and Their Transporters in T Cell Immunity and Cancer Therapy. Mol Cell (2020) 80:384–95. doi: 10.1016/j.molcel.2020.09.006
13. Kelly B, Pearce EL. Amino Assets: How Amino Acids Support Immunity. Cell Metab (2020) 32:154–75. doi: 10.1016/j.cmet.2020.06.010
14. Wei J, Raynor J, Nguyen TL, Chi H. Nutrient and Metabolic Sensing in T Cell Responses. Front Immunol (2017) 8:247. doi: 10.3389/fimmu.2017.00247
15. Shyer JA, Flavell RA, Ballis W. Metabolic signaling in T cells. Cell Res (2020) 30:649–59. doi: 10.1038/s41422-020-0359-5
16. Teng X, Cornaby C, Li W, Morel L. Metabolic regulation of pathogenic autoimmunity: therapeutic targeting. Curr Opin Immunol (2019) 61:60–6. doi: 10.1016/j.coi.2019.07.001
17. Morel L. Immunometabolism in systemic lupus erythematosus. Nat Rev Rheumatol (2017) 13:280–90. doi: 10.1038/nrrheum.2017.43

AUTHOR CONTRIBUTIONS

MK, NY, and GT conceptualized the article, reviewed the literature, and wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the United States National Institutes of Health grants R01AR064350, R37 AI 49954 (to GT), AMED under Grant Number JP 20ek0410078, a SENSHIN Medical Research Foundation grant (to MK), and Gilead Sciences research scholars program in rheumatology (to NY).
44. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium flux in patients with clinically active systemic lupus erythematosus resistant to, or failed therapy. *J Immunol* (2016) 196:2479–86. doi: 10.4049/jimmunol.1600312

45. Shah D, Sah S, Nath SK. Interaction between glutathione and apoptosis in systemic lupus erythematosus. *Autoimmun Rev* (2013) 12:741–51. doi: 10.1016/j.autrev.2012.12.007

46. Perl A. Review: Metabolic Control of Immune System Activation in Rheumatic Diseases. *Arthritis Rheumatol* (2017) 69:2259–70. doi: 10.1002/art.40223

47. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N, et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. *Nat Immunol* (2008) 9:1157–64. doi: 10.1038/ni.1645

48. Wang P, Xu Y, Zhang G, Ma X. Branched Chain Amino Acids: Anergic T cells are controlled by glutamine and faa00086

49. Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras EF. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). *Lupus* (2001) 10:258–65. doi: 10.1191/0962891001604990

50. Suwannaraj S, Lagoa A, Keisler D, McMurray RW. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). *Lupus* (2001) 10:258–65. doi: 10.1191/0962891001604990

51. Xu T, Stewart KM, Wang X, Liu K, Xie M, Kuo Y, et al. Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism. *Nature* (2017) 548:228–33. doi: 10.1038/nature23475

52. Choi SC, Titov AA, Abboud G, Seay HR, Brusko TM, Roopenian DC, et al. Inhibition of mammalian target of rapamycin selectively targets autoreactive follicular helper T cells. *Nat Commun* (2016) 7:13936. doi: 10.1038/ncomms13936

53. Kato H, Perl A. Mechanistic target of rapamycin complex 1 expands Th17 and suppresses regulatory CD4+CD25+FoxP3+ T cells. *J Immunol* (2011) 186:4107–16. doi: 10.4049/jimmunol.1100463

54. Suwannaraj S, Lagoa A, Keisler D, McMurray RW. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). *Lupus* (2001) 10:258–65. doi: 10.1191/0962891001604990

55. Battu S, Minhas G, Mishra A, Khan N. Amino Acid Sensing via General Control nonderepressible 2 (GCN2) controls TH9 cells and allergic inflammation. *J Allergy Clin Immunol* (2016) 138:1299–307. doi: 10.1016/j.jaci.2016.05.027

56. Shah D, Sah S, Nath SK. Interaction between glutathione and apoptosis in systemic lupus erythematosus. *Autoimmun Rev* (2013) 12:741–51. doi: 10.1016/j.autrev.2012.12.007

57. Perl A. Review: Metabolic Control of Immune System Activation in Rheumatic Diseases. *Arthritis Rheumatol* (2017) 69:2259–70. doi: 10.1002/art.40223

58. Ray JP, Staron MM, Shyer JA, Ho PC, Marshall HD, Gray SM, et al. The IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in vivo. *J Biol Chem* (2017) 292:1528–39. doi: 10.1074/jbc.M117.819741

59. Xu T, Stewart KM, Wang X, Liu K, Xie M, Kuo Y, et al. Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism. *Nature* (2017) 548:228–33. doi: 10.1038/nature23475

60. Chen Y, Wang C, Wang B, Wang X, Wang Y, An J, et al. Restoring T-helper 17 cell/regulatory T-cell balance and decreasing disease activity by rapamycin and all-trans retinoic acid in patients with systemic lupus erythematosus. *Lupus* (2018) 27:393–607. doi: 10.1080/13872568.2018.1430485

61. Kono M, Yoshida N, Maeda K, Tsokos GC. Transcriptional factor ICER activation of mTOR pathway. *Nat Immunol* (2019) 20:1367–76. doi: 10.1038/s41467-019-09475-3

62. Wang P, Xu Y, Zhang G, Ma X. Branched Chain Amino Acids: Anergic T cells are controlled by glutamine and...
71. Birge RB, Boelz S, Kumar S, Carlson J, Wanderley J, Calianese D, et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. *Cell Death Differ* (2016) 23:962–78. doi: 10.1038/cdd.2016.11

72. Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. *J Lipid Res* (2009) 50 Suppl:S91–96. doi: 10.1194/jlr.R800080-JLR200

73. Chaneton B, Hillmann P, Zheng L, Martin ACL, Madaffodi ODK, Chokkathukalam A, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. *Nature* (2012) 491:458–62. doi: 10.1038/nature11540

74. Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. *Proc Natl Acad Sci U S A* (2012) 109:6904–9. doi: 10.1073/pnas.1204761109

75. Ma EH, Bantug G, Griss T, Condotta S, Johnson RM, Samborska B, et al. Serine Is an Essential Metabolite for Effecter T Cell Expansion. *Cell Metab* (2017) 25:345–57. doi: 10.1016/j.cmet.2016.12.011

76. Kono M, Maeda K, Stocton-Gavanescu I, Pan W, Umeda M, Katsuyama E, et al. Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. *JCI Insight* (2019) 4.e127395. doi: 10.1172/jci.insight.127395

77. Koga T, Ichinose K, Mizui M, Crispin JC, Tsokos GC. Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus. *J Immunol* (2012) 189:3490–6. doi: 10.4049/jimmunol.1201785

78. Maeda K, Otomo K, Yoshida N, Abu-Asab MS, Ichinose K, Nishino T, et al. CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease. *J Clin Invest* (2018) 128:3445–59. doi: 10.1172/JCI95907

79. Minton DR, Nam M, McLaughlin DJ, Condotta S, Johnson RM, Samborska B, et al. Serine-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus. *Sci Transl Med* (2020) 12:eax2220. doi: 10.1126/scitranslmed.aax2220

80. Roy DG, Chen J, Mamane V, Ma EH, Muhire BM, Sheldon RD, et al. Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming. *Cell Metab* (2020) 31:250–66.e259. doi: 10.1016/j.cmet.2020.01.006

81. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its role in metabolism and disease. *Nature* (2018) 570:194. doi: 10.1038/s41586-018-0131-5

82. Klein Geltink RJ, Pearce EL. The importance of methionine metabolism. *Elife* (2019) 8:e47221. doi: 10.7554/elife.47221

83. Sinclair LV, Howden AJ, Brenes A, Spinelli L, Hukelmann JL, Macintyre AN, et al. Antigen receptor control of methionine metabolism in T cells. *Elife* (2019) 8:e44210. doi: 10.7554/elife.44210

84. Yin Y, Choi SC, Xu Z, Perry DJ, Seay H, Croker BP, et al. Normalization of CD3+ T cell metabolism reverses lupus. *Sci Transl Med* (2015) 7:274ra218. doi: 10.1126/scitranslmed.aad0835

85. Otomo K, Koga T, Mizui M, Yoshida N, Kriegel C, Bickerton S, et al. Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-Like Disease in Mice. *J Immunol* (2015) 195:5533–7. doi: 10.4049/jimmunol.1501603

86. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. *Nat Rev Drug Discov* (2020) 20:101–24. doi: 10.1038/s41573-020-0090-8

Conflict of Interest: MK reports grants from GlaxoSmithKline plc, Mitsubishi Tanabe, Astellas, Sanofi, Taisho Pharmaceutical, NIPPON SHINYAKU CO., LTD, and Taiju Life Social Welfare Foundation, outside the submitted work. GT reports consultancies, speaking fees, or honoraria from Janssen, Novartis, ABPRO, Silicon Therapeutics, A2 Therapeutics, and Dicerna Pharmaceuticals. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor declared a past collaboration with the authors GT and NY.

Copyright © 2021 Kono, Yoshida and Tsokos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). This use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction in which does not comply with these terms.